Published in Clin Chem on January 01, 2000
Measurement of Plasma and Intracellular Concentrations of Raltegravir | NCT01214486
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS One (2013) 0.81
Intracellular accumulation of Praziquantel in T lymphoblastoid cell lines, CEM (parental) and CEMVBL(P-gp-overexpressing). BMC Pharmacol Toxicol (2016) 0.76
A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ (1998) 4.44
Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev (1997) 4.25
Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms. BMJ (2001) 3.81
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther (2007) 3.09
A systematic review of the effectiveness of promoting lifestyle change in general practice. Fam Pract (1997) 3.04
Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med (1999) 2.67
Influences on pre-hospital delay in the diagnosis of colorectal cancer: a systematic review. Br J Cancer (2007) 2.63
Requirement of low oxidation-reduction potential for photosynthesis in a blue-green alga (Phormidium sp.). Arch Microbiol (1975) 1.96
Systematic review of factors influencing patient and practitioner delay in diagnosis of upper gastrointestinal cancer. Br J Cancer (2006) 1.96
The ultimate speed of magnetic switching in granular recording media. Nature (2004) 1.89
Indinavir concentrations and antiviral effect. Pharmacotherapy (1999) 1.82
Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev (1997) 1.72
Effect of gender, age and deprivation on key performance indicators in a FOBT-based colorectal screening programme. J Med Screen (2010) 1.69
Prodrugs of nitroxyl as potential aldehyde dehydrogenase inhibitors vis-a-vis vascular smooth muscle relaxants. J Med Chem (1995) 1.68
Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS (1999) 1.66
Screening for colorectal cancer using the faecal occult blood test, hemoccult. Cochrane Database Syst Rev (2000) 1.53
Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection. Pediatr Infect Dis J (2001) 1.51
Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis (2000) 1.48
Acyclovir therapy in neonates. J Pediatr (1991) 1.45
Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS (2000) 1.45
Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut (2011) 1.45
Agents for treating human immunodeficiency virus infection. Am J Hosp Pharm (1994) 1.43
Feasibility of an evidence-based literature search service for general practitioners. Med J Aust (2001) 1.41
Colorectal cancer: implications of mass screening for public health. Med J Aust (1990) 1.40
A specificity comparison of four antisense types: morpholino, 2'-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev (1997) 1.37
Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrob Agents Chemother (2001) 1.32
Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci U S A (2000) 1.22
Concentration-controlled zidovudine therapy. Clin Pharmacol Ther (1998) 1.20
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis (2000) 1.17
Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA (1988) 1.15
How should we measure informed choice? The case of cancer screening. J Med Ethics (2005) 1.13
Effect of infusion rate on amphotericin B-associated febrile reactions. Drug Intell Clin Pharm (1988) 1.12
A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. J Pediatr (1998) 1.10
Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. J Infect Dis (2000) 1.09
Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob Agents Chemother (2000) 1.07
Communication about colorectal cancer screening in Britain: public preferences for an expert recommendation. Br J Cancer (2012) 1.07
Modifiable and fixed factors predicting quality of life in people with colorectal cancer. Br J Cancer (2011) 1.07
The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health Technol Assess (2011) 1.06
Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children. J Infect Dis (2000) 1.04
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Res Hum Retroviruses (2000) 1.02
Clinical pharmacokinetics of zidovudine. An update. Clin Pharmacokinet (1996) 1.00
Personalised cancer follow-up: risk stratification, needs assessment or both? Br J Cancer (2012) 0.98
Indinavir plasma protein binding in HIV-1-infected adults. AIDS (2000) 0.97
Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation (1991) 0.97
A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team. Pediatrics (1999) 0.96
Primary care-based physical activity programs: effectiveness in sedentary older patients with osteoarthritis symptoms. Arthritis Rheum (2001) 0.96
Evaluation of antisense mechanisms of action. Methods Enzymol (2000) 0.96
Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics (1996) 0.95
Follow-up care for men with prostate cancer and the role of primary care: a systematic review of international guidelines. Br J Cancer (2009) 0.94
Depression and anxiety in patients repeatedly referred to secondary care with medically unexplained symptoms: a case-control study. Psychol Med (2011) 0.93
Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection. Pharmacotherapy (2000) 0.93
The influence of biperiden, benztropine, physostigmine and diazepam on the convulsive effects of Cicuta douglasii. Proc West Pharmacol Soc (1978) 0.91
Treatment of resistant herpes simplex virus with continuous-infusion acyclovir. JAMA (1990) 0.88
Strategies for control of zidovudine concentrations in serum. Antimicrob Agents Chemother (1995) 0.86
Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Antimicrob Agents Chemother (1996) 0.85
A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections. Drug Saf (2000) 0.84
Mobile health for cancer in low to middle income countries: priorities for research and development. Eur J Cancer Care (Engl) (2014) 0.83
Stacking interactions of ApA analogues with modified backbones. Biopolymers (1992) 0.83
Antibacterial activity and inhibition of protein synthesis in Escherichia coli by antisense DNA analogs. Antisense Res Dev (1991) 0.81
Deroughening of a 1D domain wall in an ultrathin magnetic film by a correlated defect. Phys Rev Lett (2001) 0.80
Are women ready for the new cervical screening protocol in England? A systematic review and qualitative synthesis of views about human papillomavirus testing. Br J Cancer (2012) 0.80
Recent advances: antiinfectives. Ann Pharmacother (1995) 0.79
Informatics and e-health: advancing knowledge and improving cancer care. Eur J Cancer Care (Engl) (2014) 0.78
Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy. Pharmacotherapy (1997) 0.78
Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo. Clin Pharmacol Ther (2010) 0.78
Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). J Infect Dis (2000) 0.78
Valacyclovir. Ann Pharmacother (1997) 0.78
Affinity purification of RNA: sequence-specific capture by nonionic morpholino probes. Biotechniques (1997) 0.77
Disposition of zidovudine in obese pregnant women with human immunodeficiency virus type 1 infection. J Infect Dis (1996) 0.77
Screening for colorectal cancer: a survey of New Zealand general practitioners. N Z Med J (1996) 0.77
Ganciclovir pharmacokinetics during renal impairment. Antimicrob Agents Chemother (1988) 0.77
Integration of geriatric oncology in daily multidisciplinary cancer care: the time is now. Eur J Cancer Care (Engl) (2015) 0.76
Clinical practice guidelines and Australian general practice. Contemporary issues. Aust Fam Physician (1999) 0.76
Cytomegalovirus infections in the immunocompromised transplant patient. Prevention of cytomegalovirus disease with oral acyclovir. Transplant Proc (1991) 0.76
Potential confusion with antiretroviral drugs. Am J Health Syst Pharm (1998) 0.75
The placental transport and use of acyclovir in pregnancy. J Lab Clin Med (1992) 0.75
Detecting colorectal cancer in primary care. Aust Fam Physician (1999) 0.75
Registries and the prevention of colorectal cancer. Ital J Gastroenterol Hepatol (1999) 0.75
Carbethoxylating agents as inhibitors of aldehyde dehydrogenase. J Med Chem (1995) 0.75
Introduction to the "HIV and AIDS" column. Ann Pharmacother (1992) 0.75
Rehabilitation at Quang Ngai. Phys Ther (1968) 0.75
Negative ion fast atom bombardment mass spectrometry of oligodeoxynucleotide carbamate analogs. Biomed Environ Mass Spectrom (1988) 0.75
Antiretroviral drug interactions. Int J Antimicrob Agents (1995) 0.75
Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation. Pharmacotherapy (1995) 0.75
Themes for our journal: 2014-2016. Eur J Cancer Care (Engl) (2014) 0.75
[Clinical observations of Rheomacrodex and Rheomacrodex with sorbite in cerebrovascular circulation disorders]. Med Welt (1970) 0.75
Stable ultrahigh-density magneto-optical recordings using introduced linear defects. Nature (2001) 0.75
Negative screening colonoscopy after a positive guaiac faecal occult blood test: not a contraindication to continued screening. Colorectal Dis (2012) 0.75
Albumin/globulin rations, colloid osmotic pressures and Lowry protein microanalysis in rat plasma. Clin Sci Mol Med Suppl (1978) 0.75
Counterpoint: let's expand the formulary system and renew its vigor. Am J Hosp Pharm (1986) 0.75
Pentamidine concentrations in a mother with AIDS and in her neonate. Clin Infect Dis (1995) 0.75
Assisting manual dolphin identification by computer extraction of dorsal ratio. Ann Biomed Eng (2000) 0.75
Pharmacist interventions to improve prescribing of vancomycin and tobramycin. Am J Hosp Pharm (1986) 0.75
Effect of blood exchange on acyclovir clearance in an infant with neonatal herpes. J Pediatr (1987) 0.75
Atrial septal defect. A nursing care plan. AORN J (1984) 0.75
A comparison of the prevalence of respiratory illness and non-specific health symptoms in two Victorian cities. Aust N Z J Public Health (2001) 0.75